Literature DB >> 9546911

Quality of life in patients with intermittent claudication: relationship with laboratory exercise performance.

G Barletta1, S Perna, C Sabba, A Catalano, C O'Boyle, G Brevetti.   

Abstract

In patients with peripheral arterial disease, limitation of exercise capacity will reduce the level of everyday physical activity and affect the quality of life. This study was designed (1) to examine the health-related quality of life of patients with intermittent claudication, and (2) to verify whether treadmill performance is related to the patient's perceived ability to function in the community. In 251 patients with intermittent claudication and 89 matched normal subjects, quality of life was assessed by a general health index questionnaire, the McMaster Health Index Questionnaire (MHIQ), which covers three dimensions of life (physical, social and emotional function). The maximal walking capacity of intermittent claudication patients was measured by the treadmill test. When controls were compared to intermittent claudication patients using the MHIQ, it was found that intermittent claudication patients showed a significant (p < 0.01) impairment of 'general health' and lower scores for physical (0.90 +/- 0.17 vs 0.65 +/- 0.17; p < 0.01), social (0.71 +/- 0.11 vs 0.63 +/- 0.12; p < 0.01) and emotional (0.75 +/- 0.17 vs 0.65 +/- 0.15; p < 0.01) function. Age, gender and work status had a significant impact upon health scores in several areas. Treadmill performance did not correlate with social or emotional function, whereas there was a small but significant relationship between maximal walking capacity and physical function scores (r = 0.197; p < 0.01). This study suggests that impairment in quality of life experience by patients with intermittent claudication poorly correlates with the reduced exercised capacity assessed by the treadmill test. Therefore, the evaluation of medical and surgical treatment of intermittent claudication should include the administration of a questionnaire for quality of life assessment.

Entities:  

Mesh:

Year:  1996        PMID: 9546911     DOI: 10.1177/1358863X9600100102

Source DB:  PubMed          Journal:  Vasc Med        ISSN: 1358-863X            Impact factor:   3.239


  13 in total

1.  Patterns of ambulatory activity in subjects with and without intermittent claudication.

Authors:  Andrew W Gardner; Polly S Montgomery; Kristy J Scott; Azhar Afaq; Steve M Blevins
Journal:  J Vasc Surg       Date:  2007-10-24       Impact factor: 4.268

2.  Relationship between health status and utility measures in older claudicants.

Authors:  B A Bartman; M J Rosen; D D Bradham; J Weissman; M Hochberg; D A Revicki
Journal:  Qual Life Res       Date:  1998-01       Impact factor: 4.147

3.  Intermittent claudication: pharmacoeconomic and quality-of-life aspects of treatment.

Authors:  Gregorio Brevetti; Roberta Annecchini; Roxanna Bucur
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 4.  Assessment of functional status and quality of life in claudication.

Authors:  Ryan J Mays; Ivan P Casserly; Wendy M Kohrt; P Michael Ho; William R Hiatt; Mark R Nehler; Judith G Regensteiner
Journal:  J Vasc Surg       Date:  2011-02-18       Impact factor: 4.268

5.  Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study.

Authors:  Timothy P Murphy; Donald E Cutlip; Judith G Regensteiner; Emile R Mohler; David J Cohen; Matthew R Reynolds; Joseph M Massaro; Beth A Lewis; Joselyn Cerezo; Niki C Oldenburg; Claudia C Thum; Suzanne Goldberg; Michael R Jaff; Michael W Steffes; Anthony J Comerota; Jonathan Ehrman; Diane Treat-Jacobson; M Eileen Walsh; Tracie Collins; Dalynn T Badenhop; Ulf Bronas; Alan T Hirsch
Journal:  Circulation       Date:  2011-11-16       Impact factor: 29.690

Review 6.  [Quality of life and peripheral obliterative arteriopathy. Perspective for the future].

Authors:  P Priollet
Journal:  Drugs       Date:  1998       Impact factor: 9.546

Review 7.  [Evaluation of the impact of peripheral obliterative arteriopathy on quality of life].

Authors:  P Marquis
Journal:  Drugs       Date:  1998       Impact factor: 9.546

8.  Effects of the 5-HT2A Antagonist Sarpogrelate on Walking Ability in Patients with Intermittent Claudication as Measured Using the Walking Impairment Questionnaire.

Authors:  Hiroshi Matsuo; Hiroshi Shigematsu
Journal:  Ann Vasc Dis       Date:  2008-09-25

9.  Exercise performance in patients with peripheral arterial disease who have different types of exertional leg pain.

Authors:  Andrew W Gardner; Polly S Montgomery; Azhar Afaq
Journal:  J Vasc Surg       Date:  2007-05-30       Impact factor: 4.268

10.  Positive and negative well-being of older adults with symptomatic peripheral artery disease: A population-based investigation.

Authors:  Snorri Bjorn Rafnsson; Gerry Fowkes
Journal:  JRSM Cardiovasc Dis       Date:  2020-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.